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Abstract
Malignant gliomas are the most common primary brain tumors. Grade III and IV gliomas harboring wild-type IDH1/2 
are the most aggressive. In addition to surgery and radiotherapy, concomitant and adjuvant chemotherapy with 
temozolomide (TMZ) significantly improves overall survival (OS). The methylation status of the O6-methylguanine-DNA 
methyltransferase (MGMT) promoter is predictive of TMZ response and a prognostic marker of cancer outcome. However, 
the promoter regions the methylation of which correlates best with survival in aggressive glioma and whether the 
promoter methylation status predictive value could be refined or improved by other MGMT-associated molecular markers 
are not precisely known. In a cohort of 87 malignant gliomas treated with radiotherapy and TMZ-based chemotherapy, we 
retrospectively determined the MGMT promoter methylation status, genotyped single nucleotide polymorphisms (SNPs) 
in the promoter region and quantified MGMT mRNA expression level. Each of these variables was correlated with each 
other and with the patients’ OS. We found that methylation of the CpG sites within MGMT exon 1 best correlated with OS 
and MGMT expression levels, and confirmed MGMT methylation as a stronger independent prognostic factor compared to 
MGMT transcription levels. Our main finding is that the presence of only the A allele at the rs34180180 SNP in the tumor 
was significantly associated with shorter OS, independently of the MGMT methylation status. In conclusion, in the clinic, 
rs34180180 SNP genotyping could improve the prognostic value of the MGMT promoter methylation assay in patients with 
aggressive glioma treated with TMZ.
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Introduction
Malignant gliomas are the most common primary brain tumors. 
The World Health Organization (WHO) classifies them in four 
grades, based on their malignancy. Malignant anaplastic astro-
cytoma (WHO grade III) and glioblastoma multiforme (GBM; 
WHO grade IV) are rapidly progressive and aggressive cancers 
with a short patient survival time after diagnosis. The standard 
management includes surgery, radiotherapy and concomitant 
temozolomide (TMZ) chemotherapy, followed by adjuvant TMZ. 
Treatment with this alkylating agent significantly improves 
both overall and progression-free survival of patients with 
newly diagnosed GBM, although the response is heterogene-
ous (1,2). Molecular markers to predict TMZ effectiveness have 
been identified. For instance, the methylation status of the O6-
methylguanine-DNA methyltransferase (MGMT) gene promoter 
appears to be predictive of the TMZ response in patients with 
newly diagnosed GBM (3–5). This predictive feature has recently 
been confirmed also in patients with grade III glioma harboring 
wild type (about 30% of all grade III gliomas) (6), but not mutant 
Isocitrate Dehydrogenase 1 (IDH1) (7).
The predictive value of MGMT promoter methylation can 
be explained by the function of MGMT, a conserved DNA repair 
protein that removes DNA adducts, such as those induced 
by alkylating agents, and restores the normal nucleotide (8). 
Therefore, MGMT can antagonize TMZ genotoxic effects, lead-
ing to tumor resistance. Accordingly, malignant gliomas in 
which MGMT expression is repressed by promoter methylation 
are more likely to respond to alkylating anticancer drugs (9). 
Consequently, much effort has been focused on the identifica-
tion of the MGMT promoter regions the methylation of which 
correlates best with gene repression. This led to the discovery 
that the methylation status of few CpG sites in the downstream 
promoter region that overlaps with exon 1 and a cis-acting 
enhancer sequence best reflects MGMT expression status (10–
13). Although methylation of this region is consistently associ-
ated with better clinical response to TMZ treatment (5,12,14), it 
remains to be established whether it also best correlates with 
overall survival (OS) (12,13,15).
Moreover, a clinical decision should not be based only on 
the MGMT promoter methylation status, because discrepan-
cies between methylation status and MGMT expression level 
have been observed in up to 20% of patients with GBM (10,16). 
This suggests the existence of an additional methylation-inde-
pendent mechanism of MGMT expression regulation. Gene 
alterations could account for this mechanism. For instance, 
loss of heterozygosity (LOH) at chromosome 10q, where MGMT 
is located (10q26.1), is frequently found in patients with GBM 
(17) and has been associated with a better response to TMZ-
based therapy (18). Similarly, a recent study on 61 patients with 
GBM showed that 70% of them had a loss of 10q26.1 and further 
stressed that silencing of MGMT results from combined effect of 
genetic loss and methylation (19). More subtle genetic defects 
could also influence MGMT transcriptional activity. For instance, 
in colorectal carcinoma (20) and lung cancer (21), the c.-56 C>T 
(rs16906252) single-nucleotide polymorphism (SNP) located in 
the downstream MGMT promoter region strongly influences 
MGMT methylation and expression. Its effect in malignant glio-
mas remains controversial. In patients with GBM, association of 
the T allele of rs16906252 with MGMT promoter methylation and 
longer survival was recently shown in two studies (14,22) but 
not in two others (5,23). The effect on MGMT expression and/or 
clinical outcome of the other referenced SNPs within or close 
to the MGMT promoter is poorly documented. Only one recent 
study described some haplotypes (several associated SNPs) in 
the promoter/enhancer region of MGMT that variably influence 
MGMT promoter activity and consequently its expression (24).
To identify MGMT-associated molecular markers that could 
help refining/improving or even substitute the MGMT methyla-
tion assessment as a predictor of TMZ effectiveness, we ret-
rospectively analyzed a cohort of 87 patients with malignant 
aggressive glioma who were treated with radiotherapy and 
alkylating agent-based chemotherapy after tumor resection. 
We determined MGMT methylation status and expression lev-
els and the SNP genotype in its promoter region. Each of these 
molecular markers was correlated with each other and with the 
patients’ OS. Our study confirms that MGMT promoter meth-
ylation is associated with a significant survival benefit in these 
patients. Moreover, the variant c.-368G>A (rs34180180) located 
in the MGMT promoter was significantly associated with glioma 
aggressiveness. OS was shorter in TMZ-treated patients with 
tumors carrying only the A allele. The deleterious effect of the 
c.-368G>A variant on survival was robust and independent of 
the MGMT promoter methylation status.
Materials and methods
Patients and samples
Glioma samples (n = 87) resected between 2007 and 2014 were obtained 
from three institutions: the Neurosurgery Unit at the Clermont-Ferrand 
University Hospital Center, France (n  =  50) (‘Tumorothèque Auvergne 
Gliomes’, ethical approval DC-2012-1584), the Neurosurgery unit at the 
Poitiers University Hospital Center, France (n = 10) (Tumorothèque Poitiers 
DHOS/OPRC/FCnotif-tumoro-jun04: ethical approval 04056)  and the 
Neurosurgery Department, Hospital de Braga, Portugal (n = 27). This study 
was approved by the ethics committees and the respective competent 
authorities. Patients signed a written individual informed consent accord-
ing to institutional guidelines and samples were anonymized.
Tumor samples were the remaining material after the standard diag-
nostic/prognostic analyses. Immediately after surgery, samples were 
snap-frozen and stored in liquid nitrogen. Random sections of each tumor 
were analyzed under a light microscope after hematoxylin–eosin staining 
to determine the extent of necrosis and the percentage of tumor cells. 
The 87 glioma samples all had more than 50% of tumor cells. Tumor his-
tological diagnosis and grading were based on the WHO criteria. Four 
non-tumoral control samples of the corpus callosus (n  =  1) and frontal 
cortex (n = 3) (white matter enriched in astrocytes and oligodendrocytes 
from which gliomas originate) were from the Brain and Tissue Bank of 
the Maryland (mean age of the donors: 27.3 ± 2 years). The four controls 
samples and 50/87 gliomas were homogenized by cryogenic grinding. 
Each homogenate was equally distributed in vials and used for matched 
genomic DNA and RNA extraction. For the other 37 gliomas, only genomic 
DNA was available. DNA was isolated from (i) frozen tissues (n = 27 sam-
ples from Braga hospital and 50 samples from Clermont-Ferrand hospital) 
using the QIAamp DNA Mini Kit (Qiagen, Hamburg, GmbH), according to 
the manufacturer’s recommendations, or (ii) from paraffin-tissue blocks 
(n = 10 samples from Poitiers hospital) using the FFPE DNA Extraction Kit 
(Qiagen, Hamburg, GmbH). All samples were stored at −80°C until use.
OS was calculated as the number of days between the surgery date and 
the patient’s death. Tumor resection was classified as gross total resec-
tion (GTR), when no enhanced contrast was detected 48 h postsurgery, or 
Abbreviations 
GBM glioblastoma multiforme
HR hazard ratio
LOH loss of heterozygosity
OS overall survival
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as partial resection (PR), when enhanced contrast was still detected 48 h 
postsurgery.
IDH1 mutation analysis and MGMT SNP genotyping
IDH1 genotyping was performed by EpigenDx (Worcester, MA) in 50 tumor 
samples (EpigenDx pyrosequencing assays ADS1703 and ADS1704). In the 
other 37 samples, we analyzed the most frequent IDH1 mutations in exon 
4 (codon 132) using PCR-RFLP (25).
For MGMT SNP genotyping, tumor (n = 87) and, when available, blood 
(n = 27) genomic DNA samples were PCR-amplified using 0.5 µM of each 
primer (5′–3′: AGGCTCTGGCAGTGTCTAGG and AAAGGCTGGGCAACACCT 
and the Kapa 2G Robust Hotstart Ready mix (Kapabiosystems, Boston) 
according to the manufacturer’s instructions (annealing temperature: 
60°C). The obtained 938-bp MGMT fragment encompassing 16 SNPs (from 
rs1625649 to rs149452540) was sequenced by GATC Biotech (Mulhouse, 
France).
MGMT methylation analysis
The MGMT promoter and exon 1 methylation status in 50 tumors and 
the four controls was determined by EpigenDx (Worcester, MA) using the 
bisulfite based-pyrosequencing assays ASY514FS1/ASY514FS3/ASY470FS1. 
Data were provided as the methylation percentage of the 21 CpG sites 
analyzed (their GRCh37:Hg19 coordinates are provided in Supplementary 
Figures 1 and 2, available at Carcinogenesis Online).
For the other 37 tumor DNA samples, MGMT methylation status was 
analyzed using the PyroMark MGMT kit (Qiagen). Chemically methylated 
and unmethylated human genomic DNA controls (EpiTect PCR Control 
DNA Set, Qiagen) were included in each batch. Briefly, 40 ng of tumor DNA 
were bisulfite-modified using the EZ DNA methylation kit (Zymo Research, 
Orange, CA) according to the manufacturer’s recommendations. The CpG 
pyrosequencing methylation assay using the Qiagen kit was performed 
on a PSQ 96 MA system (Qiagen) according to the manufacturer’s proto-
col. The PyroMark MGMT kit quantifies the level of methylation of five 
individual CpG sites within exon 1 of MGMT using the Pyromark CpG soft-
ware (Qiagen). The MGMT promoter was defined as unmethylated when 
the mean methylation of the five CpG sites was <8%, and as methylated 
when ≥8% (14).
MGMT expression analysis
Total RNA was isolated from 50 tumors using the RNeasy Mini Kit (Qiagen, 
Hamburg, GmbH). The RNA quality was tested on an Agilent Bioanalyzer 
(Agilent) according to the manufacturer’s instructions and only samples 
with RIN >6 (n = 35) were retained for RT-QPCR analysis.
Two independent reverse transcription reactions were performed 
using 250 ng of RNA and the High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems) according to the manufacturer’s instructions. 
Quantitative PCR was performed on a Taqman 7300 apparatus using the 
Taqman Probe technology (Applied Biosystems) with specific primers and 
probes (Taqman Gene Expression Assay): FAM Hs01037698_ml (MGMT) and 
VIC Hs02800695_ml (HPRT1). About 4 µl of cDNA (diluted 1:5) were ampli-
fied with 1× Taqman Gene Expression Master Mix (Applied Biosystems) 
and 1× Taqman Gene Expression Assay in a final volume of 20 µl. The pro-
gram included an initial step of incubation with uracil-DNA glycosylase 
(UDG) at 50°C for 2 min and a step of enzyme activation at 95°C for 10 min 
followed by 40 cycles of 95°C for 15 s, 60°C for 1 min. The cycle of threshold 
(Ct) values were used to calculate MGMT expression, normalized to HPRT1 
levels. Expression levels were calculated using the 2−ΔΔCt equation with 
ΔCt = Ct (MGMT gene) – Ct (HPRT1 gene) and ΔΔCt = ΔCt (tumor) – mean 
ΔCt (non-neoplastic tissues) (26). For each condition, the presented data 
were obtained from two independent qPCR experiments, each analyzed 
in duplicate.
Copy-number variation assay
The copy-number assay has been performed using the CytoScan HD array 
from Affymetrix.This technology analysed more than 2.6 millions copy 
number markers among them 750 000 SNP and 1.9 million non-polymor-
phic markers, in order to ensure high-resolution coverage of the genome. 
Array processing, and normalization were performed by the Genosplice 
platform, using GAP (Genome Alteration Print) software (27). Data analyses 
were conducted using the R software. Using this technology, we can detect 
copy-neutral LOH: 8/25 (32%) in our cohort.
Statistical analysis
Statistical analysis was performed using the Stata software, version 13 
(StataCorp, College Station, TX). Tests were two-sided, with a type I error 
set at α = 0.05. Baseline characteristics are presented as mean ± stand-
ard deviation (SD) or as median (interquartile range) for each inde-
pendent group for continuous data, and as number of patients and the 
associated percentages for categorical parameters. When appropriate, 
quantitative variables have been categorized according to statistical dis-
tribution, clinical relevance and sensitivity analyses. Variables were com-
pared between groups using the Chi-squared or Fisher’s exact test for 
categorical variables, and the Student’s t test or Mann–Whitney test for 
quantitative variables, with normality verified by the Shapiro–Wilk test 
and homoscedasticity by the Fisher–Snedecor test. To study the relation 
between quantitative parameters (expression and methylation status), 
Pearson or Spearman correlation coefficients were estimated according 
to the statistical distribution. OS was defined as the interval from surgery 
to death, regardless of the cause of death. OS curves and estimates were 
constructed using the Kaplan–Meier method. To test the prognostic value 
of the patients’ characteristics in univariate context, OS curves were com-
pared between groups using log-rank test or Prentice modified Wilcoxon 
log-rank test when the ratio of hazards were higher at early survival times 
than at late ones. The log-rank test was used in univariate analyses to test 
the prognostic value of the patients’ characteristics. Multivariate analy-
sis (Cox proportional hazards regression) was used to take into account 
the adjustment for possible confusing factors, according to the univari-
ate analysis and the clinical relevance (age, sex, grade, MGMT status). The 
proportional hazard hypotheses were verified using the Schoenfeld’s test 
and plotting residuals. The interactions between possible predictive fac-
tors were also tested. Results are expressed as hazard ratios (HRs) and 95% 
confidence intervals (CIs).
Results
Clinical features of the cohort
The 87 aggressive gliomas used in this study were classified as 
grade IV GBM (n = 59; mean age at diagnosis: 62.8 ± 9.3 years, 
range: 40–81  years) and grade III glioma (n  =  28; mean age: 
58.1 ± 11.5  years, range: 29–75  years) and all had wild-type 
IDH. All patients were treated by surgery followed by chemo-
therapy (TMZ), according to the local procedures. The median 
age at surgery for the entire cohort was 61.3  years (range: 
29–81 years). The demographic and clinical features are pre-
sented in Table 1.
OS was similar in patients with GBM [median: 18.6 months 
(13.2–45.4)] or with grade III glioma [median: 17.2 months (10.5–
24.3)], with a median survival of 18.2  months for the entire 
cohort [11.0–35.9] (Figure  1). Therefore, the 87 tumors were 
referred as ‘aggressive gliomas’. Despite the poor prognosis of 
aggressive glioma and as described previously (4), five patients 
(5.7%) displayed extended survival (>4 years) and were consid-
ered as long-term survivors (Figure 1). 
MGMT methylation and MGMT mRNA expression
The CpG island located in the 5′ region of MGMT includes 98 
CpG sites (Supplementary Figure  1, available at Carcinogenesis 
Online) that are normally unmethylated. Methylation of exon 1, 
which is embedded in the CpG island, is associated with MGMT 
expression in brain tumors and response to TMZ (5,10–13). 
However, it is not clear whether it also best correlates with OS 
(12,13,15). Therefore, to determine whether methylation of a 
specific region within the MGMT promoter best correlated with 
OS, we selected 21 CpG sites that cover the downstream pro-
moter region (CpG #72 to #78) as well as two ‘upstream’ regions 
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(CpG #7 to #14 and CpG #22 to #27) selected because their meth-
ylation is documented to be associated with MGMT expression 
(Supplementary Figure 1, available at Carcinogenesis Online) (10–
12). We then assessed their methylation status by pyrosequenc-
ing analysis in the 50/87 tumor samples with sufficient amounts 
of high-quality DNA.
We found a strong correlation between the methylation 
status of ten CpG sites and OS (*P ≤ 0.05) (univariate analyses, 
Supplementary Figure  2, available at Carcinogenesis Online). 
Three of these CpG sites (#10, *P = 0.039; #26, *P = 0.03; and #27, 
*P = 0.03) were located upstream of the ATG. The other seven 
were in a row within exon 1, between positions +14 and +46 
after the ATG codon (#72, **P = 0.009; #73, **P = 0.009; #74, ***P ≤ 
0.001; #75, **P = 0.004; #76, *P = 0.025; #77, **P = 0.008; and #78, 
*P = 0.03) (Supplementary Figure 1, available at Carcinogenesis 
Online). In addition, the mean methylation of these seven 
CpGs best correlated with OS (**P = 0.002). Methylation of five 
of these seven CpG sites (#74 to #78) can be assessed also 
using a standardized commercial kit (PyroMark MGMT Kit, 
Qiagen) that was used for the 37 remaining tumors with lim-
ited amount of DNA. Therefore, for the successive analyses 
concerning MGMT promoter methylation, we used the mean 
percentage of methylation at these five CpG sites for all the 
87 samples.
In the whole cohort, the level of methylation ranged from 0 to 
60.6% (mean: 14 ± 17%, median: 3.1%) (Table 1). With the methyla-
tion cut-off value of 8%, which is generally used in the literature 
to evaluate MGMT promoter methylation status (4,14), we found 
a 2-year survival rate of 58.7% in patients with MGMT promoter 
methylation (≥8%) and of 20.2% for patients with unmethyl-
ated MGMT (<8%) (**P = 0.004; Table 2). The median survival was 
16.8  months for patients with MGMT methylation <8% (61.6%) 
and 27.6  months for patients with MGMT methylation ≥8% 
(38.4%). The HR for death was 0.39 (95% CI: 0.21–0.74), indicating 
a 61% relative reduction in the risk of death for patients with 
MGMT methylation ≥8%. These results confirm that MGMT meth-
ylation status is a positive prognostic factor in patients with 
aggressive glioma.
To test the prognostic effect of MGMT expression relative to 
MGMT promoter methylation, we then quantified MGMT tran-
script level in the 35 tumors with high-quality mRNA. MGMT 
expression in the tumors was reduced by ~40% compared to 
control brain tissue samples (Figure 2A). When we used the first 
quartile of MGMT expression as cut-off (Q1 = 0.41 fold change 
compared to control) and the Tarone–Ware test for equality 
of survivor functions, we found a significant survival advan-
tage for patients with low-expressing tumors (<Q1) (HR = 2.14 
and 95% CI: 0.93–2.92; *P  =  0.02, Table  2). The 2-year survival 
rate was 77.7% in patients with low MGMT mRNA expression 
(<Q1) and 11.5% in patients with high MGMT expression (≥Q1). 
The median survival was 28.5 months for patients with MGMT 
expression < Q1 (25.7%) and 13.2  months for patients with 
MGMT expression ≥ Q1 (74.2%). Kaplan–Meier survival curves 
(Figure  2B) validated MGMT expression as a significant prog-
nostic marker at 2 years.
We then evaluated the robustness of MGMT expression as 
a prognostic marker relative to MGMT promoter methylation. 
Overall, MGMT expression correlated negatively with the pro-
moter methylation status (Pearson correlation: r  =  −0.6, ***P  
≤ 0.001). The median mRNA expression (in fold change) in meth-
ylated (≥8%) and unmethylated (<8%) tumors was 0.42 (range: 
0.15–1.26) and 0.83 (range: 0.24–2.29), respectively, in comparison 
with 0.62 in the whole cohort and to 0.96 (range: 0.76–1.86) in the 
four control samples (Figure 2A).
We observed discordant findings in nine patients (25.7%): 
MGMT methylation (≥8%) co-occurred with high mRNA expres-
sion (≥Q1) in seven patients, and methylation <8% with low 
expression levels (<Q1) in two patients.
Multivariate Cox analysis (see Methods) (Table 2) highlighted 
that MGMT expression was still linked to survival, independently 
of MGMT methylation (HR = 7.40, 95% CI: [1.42–38.69], *P  = 0.02). 
However, MGMT methylation was a stronger independent prognos-
tic factor (HR = 0.28, 95% CI: 0.11–0.73, **P = 0.009). After adjusting 
for MGMT expression, MGMT promoter methylation still showed a 
statistically significant effect on overall survival (analysis of group 
comparisons by Cox regression, *P ≤ 0.05; Table 2). This confirms 
the robustness of MGMT promoter methylation as an independent 
prognostic factor in our population of aggressive gliomas.
Table 1. Demographic and molecular features of the 87 patients with 
aggressive glioma
Characteristicsa Nb of patients %
Sex
 Male 51/87 59
 Female 36/87 41
Age at diagnosis (years) 87/87
 Mean (SD) 61.3 (10.2)
 Range 29–81
Treatment
 R + TMZ = ‘Stupp’ 87/87 100
Resection
 Total 43/84 51
 Partial 41/84 49
Presence of IDH1 mutation 0/87 0
Presence of LOH on 1Oq 25/25 100
Presence of 1p19q codeletion 3/47 6
MGMT promoter methylation 86/87
 Non-methylated (<8%) 53/86 61.6
 Methylated (≥8%) 33/86 38.4
MGMT expression 35/87
 Mean (SD) 78% (40)
 Median 62%
 Range 15–229%
 First quartile = Q1 41%
Polymorphic SNP genotypes in tumors
 rs1625649 Only C:35/49 72
Only A:10/49 20
A/C:4/49 8
 rs113813075 Only A:1/50 2
A/C:2/50 5
Only C: 47/50 93
 rs34180180 Only A: 7/87 8
A/G: 4/87 4.6
Only G: 76/87 87.4
 rs34138162 Only A:1/50 2
A/C:1/50 2
Only C:48/50 96
 rs181536588 Only A:1/47 2
Only T:46/47 98
 rs16906252 Only C:73/80 91
C/T: 2/80 3
Only T: 5/80 6
Overall survival (months)
 Median 18.2
 Range 11.0–35.9
aMGMT methylation is the mean of the methylation of five CpG sites located 
between the Hg19 coordinates: 131265507 to 131265526 (CpG sites #74 to #78 in 
Supplementary Figure 1, available at Carcinogenesis Online).
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Nevertheless, this prognostic marker is not 100% specific. Eight 
patients with high level of MGMT promoter methylation (>30%) 
had a shorter OS (below 16.8 months, the median OS in patients 
with unmethylated promoter), and three patients with unmethyl-
ated MGMT promoter (<8%) were still alive after 27.6 months (the 
median OS for patients with methylated promoter) (Figure 3A).
Figure 1. Kaplan–Meier survival curves of our cohort (87 patients with aggressive glioma). (A) Kaplan–Meier survival curves of patients with grade III glioma (n = 28 
patients, median OS: 17.2 months) or GBM (n = 59 patients, median OS: 18.6 months) (WHO glioma classification). (B) Kaplan–Meier survival curves of the whole cohort 
of 87 patients with aggressive glioma (median OS: 18.2 months). 
Figure 2. MGMT mRNA expression is correlated with OS. (A) MGMT mRNA expression measured as fold change relative to HPRT1 (see, Material and Methods) in controls 
(normal brain tissue; n = 4), aggressive gliomas (n = 35 tumors with good quality mRNA) and aggressive gliomas with methylated (≥8%; n = 14) or non-methylated MGMT 
promoter (<8%; n = 21). Horizontal bars indicate the medians (0.96, 0.62, 0.42 and 0.83, respectively). The black line indicates the cut-off value (first quartile, Q1 = 0.41 
fold change) used to distinguish tumors with low (<Q1) or high (≥Q1) MGMT mRNA expression. (B) Kaplan–Meier survival curves based on the classification of patients 
according to the tumor MGMT mRNA expression: high (≥Q1; n = 14) or low (<Q1; n = 21), with Q1 = 0.41 (fold change).
Table 2. Association between demographic characteristics, molecular markers and overall survival in our cohort
Demographic and molecular features
Univariate analysis Multivariate analysis
Log-rank P (OS) Hazard ratio  95% CI P (OS) Hazard ratioa  95% CI
Sex (female versus male) 0.70 0.9 0.52–1.56 — — —
Age at diagnosis (years) 0.03 1.02 1.01–1.05 0.02 1.04 1.01–1.08
Resection (complete versus partial) 0.24 0.72 0.42–1.25 0.79 1.12 0.47–2.62
MGMT expression (≥ versus < Q1) 0.02 2.14 0.93–2.92 0.02 7.40 1.42–38.69
MGMT methylation (≥ versus < 8%) 0.004 0.39 0.21–0.74 0.009 0.28 0.11–0.74
Polymorphic SNP
 rs1625649 0.20 NA NA — — —
 rs113813075 0.15 NA NA — — —
rs34180180
 Only A versus A/G 0.06 NE NE NE NE NE
 Only A versus only G <0.001 0.17 0.07–0.44 0.02 0.18 0.04–0.70
 Only A versus only G + A/G <0.001 0.17 0.06–0.42 0.01 0.17 0.04–0.69
 rs34138162 0.006a NA NA — — —
 rs181536588 <0.001a NA NA — — —
 rs16906252 (T/T+C/T versus C/C) 0.56 0.77 0.32–1.82 — — —
CI, confidence interval; NA, not available; NE, not evaluated (the four patients with the A/G genotype for rs34180180 are all alive).
aThe significant effect was due to the low number of tumors with low-frequency genotypes (2/50 patients with the A allele for rs34138162; and 1/47 patient with the 
A allele for rs181536588).
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Presence of only the A allele at the c.-368G>A 
(rs34180180) SNP is associated with shorter survival 
in aggressive gliomas
With the aim of identifying methylation-independent MGMT 
gene-related factors that could be associated with survival, we 
investigated 16 SNPs (from rs1625649 to rs149452540) located in 
the MGMT promoter and exon 1. Most of the less frequent vari-
ants of these SNPs show low allelic frequency in the European 
populations (Supplementary Table 1A, available at Carcinogenesis 
Online). Consistently, only six of the 16 SNPs were polymorphic in 
our cohort (Table 1, Supplementary Figure 1 and Supplementary 
Table  1B, available at Carcinogenesis Online). Among them, 
none was found associated with MGMT expression and only 
rs16906252 was associated with MGMT methylation (**P = 0.003), 
in agreement with previous studies (14,22). More interestingly, 
the c.-368G>A SNP (rs34180180), for which 12.6% of our patients 
carried the A  allele (A/G genotype: n  =  4; A  allele only: n  =  7), 
was the only SNP significantly associated with patient survival 
(Table 2) and we thus focused our analyses on it.
To evaluate LOH, we performed copy number variation anal-
yses, using the Cytoscan HD array from Affymetrix, in 25/87 
(28%) tumor samples, including four of the seven tumors carry-
ing only the A allele of rs34180180 (‘only A’) (data not shown). All 
displayed LOH at chromosome 10, suggesting that this alteration 
might be widespread in our cohort. Moreover, comparison of the 
SNP genotyping results in tumor and blood samples revealed a 
LOH of the G-carrying allele in two other ‘only A’ tumors (blood 
DNA: A/G and tumor DNA: A allele only). This indicates that at 
least six of the seven ‘only A’ tumors were hemizygous A/-.
We then split our cohort in three groups, according to the 
tumor genotype at the rs34180180 SNP: ‘only A’ (n = 7), A/G (n = 4), 
or ‘only G’ allele (n = 76). The Kaplan–Meier survival curve indi-
cated that OS was clearly reduced in ‘only A’ carriers (log-rank test, 
***P ≤ 0.001) (Figure 4). Their median survival time was significantly 
shorter (8.52  months compared with 18.48  months for ‘only G’ 
patients). We excluded the four patients with the A/G genotype, 
who are all still alive, from further statistical analyses because of 
the short follow-up (mean of 10.8 months, two times shorter than 
the median survival time of ‘only G’ patients) and low number.
To measure the robustness of the rs34180180 genotype (‘only 
A’ and ‘only G’) as a prognostic factor and its possible association 
with MGMT promoter methylation, we compared the methyla-
tion status between groups. MGMT promoter mean methylation 
was not significantly different between groups (20.1% in ‘only A’ 
and 14.2% in ‘only G’ tumors; P = 0.23). Cox multivariate analysis 
(see Methods) indicated that the MGMT promoter methylation 
status and rs34180180 genotype were independent prognostic 
factors with an adjusted HR of 0.28 (**P = 0.009, 95% CI: 0.11–0.74) 
for the methylation status (≥8%) and 0.18 (*P  =  0.02, 95% CI: 
0.04–0.70) for the ‘only G’ genotype (Table 2). Moreover, the risk 
of death was reduced by 82% in the ‘only G’ carriers compared 
with the ‘only A’ carriers. The reduction of the death risk was 
72% in patients with methylated MGMT promoter compared 
with patients with unmethylated promoter without any synergic 
effect (Table 2, see HRs). In conclusion, the tumoral rs34180180 
A genotype in aggressive gliomas is a strong biomarker of poor 
prognosis, independently of MGMT promoter methylation, resec-
tion type, age at diagnosis and MGMT expression.
Discussion
In aggressive gliomas with wild-type IDH1, MGMT promoter 
methylation predicts a better response to alkylating agent-based 
chemotherapy and longer survival (3,4,28,29). Here, we provide 
evidence that, besides DNA methylation, the tumor genotype of 
Figure 3. Distribution of the patients depending on the tumor MGMT promoter methylation, MGMT expression, OS and rs34180180 genotypes. (A) OS (in months) in 
function of MGMT promoter methylation (mean %), n = 87 gliomas; rs34180180 genotype: A, red; A/G, green; G grey. (B) OS (in months) in function of MGMT mRNA 
expression (fold change), n = 35 gliomas; rs34180180 genotype: A, red; G, black; MGMT promoter methylation: <8% (dots) or ≥8% (triangles).
Figure  4. A allele only at the rs34180180 SNP in gliomas is associated with 
shorter survival. Kaplan–Meier survival curves based on the patients’ classifica-
tion according to the rs34180180 SNP genotype: tumors with only A (n = 7), with 
A/G (n = 4) and with only G (n = 76).
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the rs34180180 SNP, located in the MGMT promoter, is associated 
with survival in aggressive glioma.
In most studies, MGMT promoter methylation is assessed 
by analyzing a handful of CpG sites located in exon 1, in the 
downstream part of the GpG island (2,5,14). Methylation in this 
region has been consistently best correlated with MGMT expres-
sion status, compared to other part of the MGMT CpG island 
(10–13). However, only few studies comprehensively evaluated 
whether methylation in this region also correlates best with sur-
vival in patients with aggressive glioma (12). To gain insight into 
this important issue we used the quantitative pyrosequencing 
approach, which is currently the most sensitive and reproduc-
ible technique (15,30,31) to analyze this downstream promoter 
region and two other regions selected for their correlative asso-
ciation with MGMT expression (10–12). Although we observed 
a strong correlation between CpG methylation and survival 
for all three regions, methylation of the CpG sites #72 to #78, 
which are located in the downstream region, best correlated 
with survival in univariate and multivariate (with exception of 
#76) analyses (Supplementary Table 1, available at Carcinogenesis 
Online). The availability of a commercial pyrosequencing kit to 
test the CpG sites #74 to #78, and though encompassing #76, 
further facilitates this approach and allows comparing results 
from one laboratory to another. Using the mean methylation 
of the CpG sites #74 to #78 and 8% as a cut-off, we found that 
in our cohort, MGMT methylation is significantly associated 
with MGMT expression and that the mean methylation value 
is a more robust prognostic factor than MGMT expression. Our 
observations support and confirm that, currently, pyrosequenc-
ing analysis of the DNA methylation status of the CpG sites #72 
to #78 is the most relevant approach in the clinic to evaluate the 
outcome of patients with aggressive glioma harboring wild-type 
IDH1 and treated with alkylating agents.
However, the correlation between MGMT promoter methyla-
tion, MGMT expression and clinical outcome shows some dis-
crepancies. Specifically, we observed in nine patients (25.7%) 
discordances between MGMT promoter methylation and gene 
expression, in agreement with the ratio of 20% observed in other 
studies (10,16). While MGMT expression from non-tumor cells 
could have contributed to overestimate tumor MGMT expression 
in the seven patients with methylated MGMT promoter, this can-
not explain the low mRNA expression in the two glioma sam-
ples with low promoter methylation. Similarly, eight patients 
with high MGMT promoter methylation (>30%) in the tumor had 
a survival time shorter than 16.8 months (the median survival in 
patients with unmethylated tumor). Conversely, three patients 
with unmethylated promoter (<8%), survived above 27.6 months 
(the median survival for patients with methylated MGMT pro-
moter) (Figure  3A). This suggests a methylation-independent 
mechanism of MGMT expression regulation and response to 
TMZ treatment. The observation that some patients with long 
survival have unmethylated MGMT promoter and weak MGMT 
expression further supports this hypothesis (Figure 3B).
LOH at chromosome 10q, the most frequent genetic altera-
tion found in patients with GBM (60–90%) (17), can directly influ-
ence MGMT expression. The 25 samples (28%) analyzed in this 
study all displayed LOH, strongly suggesting that it is largely 
widespread in our cohort. Its prominence indicates that LOH 
at chromosome 10q cannot be used to discriminate patients 
relative to MGMT expression and response to TMZ treat-
ment. By focusing on MGMT SNPs, we found that rs34180180 
is significantly associated with patient survival in our cohort. 
Independently of the MGMT methylation status, age at diagnosis 
and surgical resection type, the presence of only the A allele in 
the tumor is a strong bad prognostic factor. Strikingly, among 
the 616 healthy Caucasian genomes sequenced in the ‘1000 
genome’ and ‘Hapmap’ projects, none display the homozygous 
A/A genotype at rs34180180 (78 A/G; 538 G/G). In addition, we 
found that at least six of the seven ‘only A’ tumors are hemizy-
gous A/-. This supports the hypothesis that in these patients, 
the presence of only one A allele in the tumor results from LOH 
for the G-carrying allele, as confirmed for the two patients for 
whom we had matched blood DNA.
Concerning the identification of a putative methylation-inde-
pendent mechanism of MGMT expression regulation, rs34180180 
is located 367 bp upstream of the ATG, in a 35bp region of the 
CpG island depleted of methylable CpG sites (Supplementary 
Figure 1, available at Carcinogenesis Online) and enriched in pre-
dicted transcription factor binding sites, as determined using 
ALGGEN (http://alggen.lsi.upc.es/). Specifically, the G to A transi-
tion at rs34180180 leads to the loss of a predicted binding site 
(TTGGCCCA) for NF-1 and C/EBP (CCAAT/enhancer binding fac-
tor) and the creation of a c-JUN binding site (TGACAAA). C-JUN 
is a members of the AP-1 family of transcription factors and a 
proto-oncogene involved in cancer onset and progression (32). 
C-JUN RNA and protein are up-regulated in aggressive gliomas, 
further contributing to the malignant properties of glioblas-
toma cells (33). We could hypothesize that in ‘only A’ tumors, 
C-JUN, or another transcription factor, contributes to MGMT 
up-regulation, independently of the DNA methylation pattern 
at the MGMT CpG island, ultimately leading to TMZ resistance 
and decreased survival. In agreement, among the seven ‘only A’ 
tumors, three are methylated (23, 32 and 60% of methylation) 
and the four (including one with methylated promoter) with 
enough RNA showed high MGMT expression (≥Q1).
Unlike two others recent studies (14,22), we did not observed 
an association between the T allele at rs1606952 and a longer 
survival in our cohort, although we detected an association 
with promoter methylation (**P = 0.003). It can be noticed that 
the number of patient carrying the T allele (7/80) is probably 
too limited to detect an association with survival. Nonetheless, 
with a similar number of patients carrying the A allele only at 
rs34180180 SNP (7/87) we observed an association with shorter 
patients’ survival, underscoring the robustness of the prog-
nostic value for this tumor genotype. In addition, and despite 
the small sample size, results associated to rs34180180 tumor 
genotype fulfill the criterions defined by Feise (34) with respect 
to statistical significance but also to magnitude of effect with 
a median survival of 8.52  months for ‘only A’ compared with 
18.48  months, for ‘only G’ patients (HR  =  0.17 [0.07  – 0.44], 
Table  2). Moreover, a sensitivity analysis (simulations about 
rs34180180 on survival) reinforces the existence of a robust 
trend for an association between rs34180180 tumor geno-
type and patient’s survival. Our pioneer study at rs34180180 
SNP paves thus the way for further validation in independent 
cohorts. Because of the absence of this non-exonic SNP in open-
access resources (i.e: exomes and SNP arrays) available at the 
cancer genome atlas database (TCGA) (http://cancergenome.
nih.gov/), dedicated molecular studies have to be conducted on 
other cohorts of aggressive gliomas.
In summary, we show that the A/- genotype of the MGMT 
rs34180180 SNP, resulting from the loss of the G-carrying 
allele, is associated with shorter OS. This is irrespective of the 
tumor MGMT methylation status and therefore, can account 
for the discordance between this marker and clinical out-
come in some patients. In the clinic, rs34180180 genotyping 
(a simple test) might improve the prognostic value of the 
MGMT promoter methylation assay in TMZ-treated patients 
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with aggressive glioma and may help to individualize clinical 
decision-making.
Supplementary material
Supplementary Figures 1 and 2 and Supplementary Table 1 can 
be found at http://carcin.oxfordjournals.org/
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